MNKD MannKind Corporation

1.69
-0.01  -1%
Previous Close 1.7
Open 1.73
Price To Book -1.9
Market Cap 348,829,926
Shares 206,408,240
Volume 7,297,856
Short Ratio
Av. Daily Volume 2,683,019
Stock charts supplied by TradingView

NewsSee all news

  1. Afrezza® (insulin human) Inhalation Powder Receives Pricing Registration in Brazil Commercial activities to commence this month

    WESTLAKE VILLAGE, Calif., Jan. 06, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that its Brazilian partner, Biomm S.A., has received written notice from the Chamber of Regulation of the

  2. Study 171 Shows Hypoglycemia is Reduced with Use of Afrezza® Relative to Insulin Aspart in Type 1 Diabetes

    WESTLAKE VILLAGE, Calif., Dec. 20, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that Hypoglycemia is reduced with use of inhaled Technosphere® Insulin relative to insulin aspart in type 1

  3. MannKind Corporation to Present at the Piper Jaffray 31st Annual Healthcare Conference

    WESTLAKE VILLAGE, Calif., Nov. 29, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such

  4. MannKind Appoints Tony Hooper to Its Board of Directors

    WESTLAKE VILLAGE, Calif., Nov. 21, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that Anthony Hooper will join its Board of Directors, effective January 1, 2020.  Mr. Hooper will also

  5. MannKind Corporation Reports 2019 Third Quarter Preliminary Financial Results

    3Q 2019 Total Revenues of $14.6 million; +227% vs. 3Q 2018°  3Q 2019 Afrezza Net Revenue was $6.4 million; +46% vs. 3Q 2018    •  Afrezza sold to our marketing partner in Brazil for launch was $0.7 million°  3Q 2019

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approved June 27, 2014.
AFREZZA
Type 1/2 diabetes
Phase 1 trial completion announced June 7, 2018.
Treprostinil Technosphere
Pulmonary Arterial Hypertension (PAH)

Latest News

  1. Afrezza® (insulin human) Inhalation Powder Receives Pricing Registration in Brazil Commercial activities to commence this month

    WESTLAKE VILLAGE, Calif., Jan. 06, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that its Brazilian partner, Biomm S.A., has received written notice from the Chamber of Regulation of the

  2. Study 171 Shows Hypoglycemia is Reduced with Use of Afrezza® Relative to Insulin Aspart in Type 1 Diabetes

    WESTLAKE VILLAGE, Calif., Dec. 20, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that Hypoglycemia is reduced with use of inhaled Technosphere® Insulin relative to insulin aspart in type 1

  3. MannKind Corporation to Present at the Piper Jaffray 31st Annual Healthcare Conference

    WESTLAKE VILLAGE, Calif., Nov. 29, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such

  4. MannKind Appoints Tony Hooper to Its Board of Directors

    WESTLAKE VILLAGE, Calif., Nov. 21, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that Anthony Hooper will join its Board of Directors, effective January 1, 2020.  Mr. Hooper will also

  5. MannKind Corporation Reports 2019 Third Quarter Preliminary Financial Results

    3Q 2019 Total Revenues of $14.6 million; +227% vs. 3Q 2018°  3Q 2019 Afrezza Net Revenue was $6.4 million; +46% vs. 3Q 2018    •  Afrezza sold to our marketing partner in Brazil for launch was $0.7 million°  3Q 2019

  6. MannKind Receives Second $12.5 Million Milestone Payment From United Therapeutics

    WESTLAKE VILLAGE, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that it has achieved the second of four specified development milestones under its licensing and

  7. MannKind Corporation to Hold 2019 Third Quarter Financial Results Conference Call on November 6, 2019

    WESTLAKE VILLAGE, Calif., Oct. 30, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2019 third quarter and year-to-date financial results and its management will host a conference call to

  8. MannKind Corporation to Present at the 2019 Cantor Global Healthcare Conference

    WESTLAKE VILLAGE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases

  9. MannKind Presents Positive Afrezza® Clinical Data from Type 1 Diabetes Study at 55th Annual Meeting of the EASD

    WESTLAKE VILLAGE, Calif., Sept. 19, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced that data from a one-year study of Afrezza® (insulin human) Inhalation Powder was presented at the 55th Annual

  10. MannKind Corporation to Present at H.C. Wainwright 21st Annual Global Investment Conference

    WESTLAKE VILLAGE, Calif., Aug. 30, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such